newsfilter.io

D.A. Wallach

Showing 1–3 of 3 transcripts.

  1. Milken Institute1h 1m

    World-class Healthcare: Investing in Biomedical Innovation

    Tanisha Carino, Christopher Hite, Bryan Johnson, Sean Parker, D.A. Wallach

    Moderated by Dr. Tanisha Carino in Abu Dhabi, this session analyzed the convergence of global biomedical innovation and market dynamics, highlighted by the historic $92 billion Bristol-Myers Squibb acquisition of Celgene as a catalyst for pipeline stability. The discussion detailed how falling hard science costs and platforms like Ginkgo Bioworks are compressing development timelines, while investment strategies increasingly favor foundational tools over singular disease treatments to address the translational gap between academic research and commercial viability. Despite concerns regarding venture capital concentration in oncology and systemic US healthcare incentives, the event projected that long-term pricing decreases and extended lifespans could emerge from global regulatory evolution and the integration of AI-driven data collection.

  2. Milken Institute58 min

    Young Entrepreneurs Who Are Rewriting the Biopharma Business Model

    Luke Timmerman, Elizabeth Iorns, Ethan Perlstein, D.A. Wallach, Alice Zhang

    In response to stagnant R&D productivity despite rapid technological advancement, a coalition of entrepreneurs including Prolara's Ethan Perlstein, Science Exchange's Elizabeth, and Verge Genomics' Alice is deploying novel business models to accelerate drug discovery. These initiatives leverage CRISPR, data science, and patient-led capital to bypass traditional inefficiencies, aiming to fail early and validate molecular hypotheses faster than legacy pharmaceutical methods allow. The panel further advocates for structural reforms in academia and big pharma to integrate computational and biological expertise, ultimately seeking to transform biotech from a chemistry-based discipline into a software-driven engineering field.

  3. Milken Institute1h 1m

    How New Investors Are Influencing Venture Capital

    Court Coursey, Chance Barnett, Troy Carter, Dave McClure, Kara Nortman, D.A. Wallach, Cort Corsi

    A panel of prominent venture capitalists and founders analyzed the current correction in valuations, emphasizing a strategic shift from unchecked growth toward capital efficiency, founder resilience, and rigorous ethical screening. The discussion highlighted emerging investment models like high-velocity seed funding and equity crowdfunding, which are addressing capital gaps in emerging markets while challenging traditional Venture Capital practices. Experts concluded that future market winners will be defined by deep cultural competence in diverse demographics and leverage on marketing innovation to navigate a more conservative, due-diligence-heavy economic landscape.